Concept Matrix Solutions, Inc. is a technology-based research and development, formulation, and manufacturing company dedicated to providing novel and cutting-edge solutions to the wellness, nutrition, veterinary and pharmaceutical industries. Our innovation in therapeutic active ingredient delivery, utilizing our proprietary technologies, is designed to help people experience healthier lives through redefining how efficacious ingredients can be administered.
CMS is comprised of key executives, preeminent scientists, developers, formulation specialists, and manufacturers of the most advanced and innovative drug delivery technologies available. The foundation of CMS’s team was instrumental in launching the first Oral Thin Film (OTF) containing an active drug ingredient in 2001. Following the successful launch of a wide variety of OTC and nutraceutical products, including, benzocaine, dextromethorphan, pediatric electrolyte supplements, and a wide range of sports nutrition products, CMS successfully launched the first OTF containing hemp extract in 2008 focused on a variety of therapeutic medical treatments. Since then, CMS has continued its research and development efforts and subsequently launched a diverse range of products featuring its patented drug delivery systems and encapsulation technologies.
Over the past several years, CMS has been actively working on innovative developments that have led to an impressive portfolio of patent filings and well-established trade secrets. This intellectual property development has an impressive range and diversity from molecular encapsulation to proprietary formulations and patented manufacturing procedures, with applications spanning through human, veterinary, agricultural industries.
CMS has continued to successfully transition technology-driven products into mass manufacturing and bring cGMP certified retail products into thriving consumer product industries. CMS exceeds the industry standards by operating and adhering to pharmaceutical and FDA drug standards with trusted analytical data, consistent measured dosing, and responsible business practices.
Tony LaRosa has been CEO of CMS since 2013. Since 2010, LaRosa has also served as VP of Business Development, Director of Product Development and Creative Director for Cure Pharmaceutical, Corp. In addition, he served as Creative Director and Business Development Consultant for InnoZen Inc. from 2002 to 2007, Zengen Inc from 2003 to 2005, as well as a creative consultant for Biotem Cytotechnologies, Inc from 1996 to 1998. From 1993 to 2005, LaRosa served as CEO of Bounce America, which was a key player in the manufacturing sector of corporate amusements for global distribution.
LaRosa has extensive hands-on experience in all facets of brand equity and marketing strategies; including concept-to-retail packaging solutions, visual and multi-media presentations, online assets, as well as seamless continuity between concept and end‐user acceptance. LaRosa studied Industrial Design at Pratt Institute in Brooklyn, NY.
David Reid brings over 2 decades of experience in the healthcare industry to CMS. Prior to leading operations at CMS, Reid served as HealthSport’s, Inc. Director of Business Development and Marketing since 2009 and assumed the same role with InnoZen, Inc. beginning in 2006. Prior to his transition into the oral thin film and drug delivery industry, Reid held positions in Strategic Planning and Consumer Marketing with Weider Health and Fitness and Weider Publications. Through his tenure he has also provided strategic business and marketing consultation for companies in the healthcare sector, including: ChronoMed, Mycratine Solutions, and Viv Publications.
Reid has blended his analytical knowledge of consumer behavior and marketing with hands on learning of product development in the nutraceutical and pharmaceutical industry, providing a unique approach to building a diverse and celebrated product mix for CMS.
Robert Davidson is CMS’s CSO and CURE’s CEO and creator of the technology. Prior to his role at CURE, he was President and CEO of InnoZen Inc., CEO of Gel Tech LLC and CEO of Bio Delivery Technologies Inc. Mr. Davidson also led the development of several drug delivery technologies and commercial brand extensions including Chloraseptic™, Suppress™, as well as Pediastrip™, and is the developer and holder of over 40 drug delivery patents. He holds a B.S. degree in Biological Life Sciences, a Master’s in Public Health, a Masters in Wellness, as well as a Master’s and Post Graduate Qualification at the University of Cambridge. Additionally, he holds a PhD in Public Health at UCN European Programs, DHA Doctorate in Health Sciences from Oklahoma State University, and Post Graduate Studies in Nanotechnology at the University of Oxford.
Brian Holler is a seasoned marketing, sales, and business development leader with over 15 years of experience in tech, startups, professional services, and CPG/retail. He has a proven track record of success in developing and executing strategies that drive growth. In his previous role as COO at Moody’s Medicinals and Greenings, he built the team for and led the development of two businesses – one in hemp, the other in cannabis – from concept to products on shelves. He is also a strong advocate for using data and analytics to inform marketing, sales, and partnership decisions.
At CMS, Brian is responsible for leading the company’s sales, marketing, and business development efforts. He will work closely with the CEO and other senior leaders to develop and execute a strategic plan that will help the company achieve its growth goals. He will also be responsible for building and managing high- performing marketing and sales teams. Brian is a graduate of Boise State University, City University, and Pacific Lutheran University, and holds MA degrees in Communication and Education, and a BA in Media Literacy/Communication.
Dr. Yenugonda is responsible for developing innovative new formulations and improving existing formulations for the company’s core market. He is an accomplished drug discovery and delivery leader with over 20 years of experience in science, technologies, business and management sectors. He has deep expertise in the development of innovative drug delivery technologies for therapeutic modalities expanded beyond small molecules to include nucleic acids, peptides, proteins and antibodies. Dr. Yenugonda’s leadership has led to new initiatives, multi-institutional programs, and multi-investigator grants. He has a proven track record in business development, including academic/pharma/CRO collaborations, evaluation and engaging in licensing and partnership opportunities. Several of his discoveries were licensed to pharma companies for commercial development and helped to initiate spin off start up biopharma companies.
With a master’s in organic chemistry and a Ph.D. in Nanomedicinal Chemistry, he served as a professor and director at Saint John’s Cancer Institute where he established the drug discovery and nanomedicine research program with the aim of developing technologies that improve patient health and enhancing the delivery of therapeutics to its target site, minimizing off-target accumulation and facilitating patient compliance. He has broad scientific knowledge in the drug product development process, including GMP, GLP, CMC, and IND application frameworks. He has contributed and held 3 issued US patents, 2 PCT, and one provisional patent; his scientific contribution is one that stands out by 32 accepted peer-reviewed manuscripts in high-impact journals. He was the recipient of multiple awards for his contribution to chemical research and he is a member of the National Academy of Inventors as well as an adjunct assistant professor at Georgetown University.
Sevan Kesenci joined the CMS team in 2022 providing his experience in e-commerce and logistic planning. Prior to joining CMS, he served as operations manager for United Surplus and Liquidation Inc from 2015-2018.
At CMS, Kesenci has taken on a directive role in all aspects of lab-scale, pilot and large-scale production. He has provided hands-on insight regarding process development, logistics as well as workforce optimization. With his B.A. in Biology from California State University Northridge, he has also taken a lead role in Research & Development relating to formulation science. His background in Biology provides CMS with a wealth of practical knowledge on the human body’s biological pathways as well as the pharmacokinetics of drug delivery.
Tony LaRosa has been CEO of CMS since 2013. Since 2010, LaRosa has also served as VP of Business Development, Director of Product Development and Creative Director for Cure Pharmaceutical, Corp. In addition, he served as Creative Director and Business Development Consultant for InnoZen Inc. from 2002 to 2007, Zengen Inc from 2003 to 2005, as well as a creative consultant for Biotem Cytotechnologies, Inc from 1996 to 1998. From 1993 to 2005, LaRosa served as CEO of Bounce America, which was a key player in the manufacturing sector of corporate amusements for global distribution.
LaRosa has extensive hands-on experience in all facets of brand equity and marketing strategies; including concept-to-retail packaging solutions, visual and multi-media presentations, online assets, as well as seamless continuity between concept and end‐user acceptance. LaRosa studied Industrial Design at Pratt Institute in Brooklyn, NY.
David Reid brings over 2 decades of experience in the healthcare industry to CMS. Prior to leading operations at CMS, Reid served as HealthSport’s, Inc. Director of Business Development and Marketing since 2009 and assumed the same role with InnoZen, Inc. beginning in 2006. Prior to his transition into the oral thin film and drug delivery industry, Reid held positions in Strategic Planning and Consumer Marketing with Weider Health and Fitness and Weider Publications. Through his tenure he has also provided strategic business and marketing consultation for companies in the healthcare sector, including: ChronoMed, Mycratine Solutions, and Viv Publications.
Reid has blended his analytical knowledge of consumer behavior and marketing with hands on learning of product development in the nutraceutical and pharmaceutical industry, providing a unique approach to building a diverse and celebrated product mix for CMS.
Robert Davidson is CURE’s CEO and founder. With over 20 years of experience, Davidson has served as CEO of InnoZen, Inc., Gel Tech LLC, and Bio Delivery Technologies Inc. He has served on multiple corporate boards. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as ChlorasepticTM, SuppressTM, as well as PediastripTM, a private label electrolyte oral thin film sold in major drug store chains.
Davidson received his B.S. degree with a concentration in Biological Life Sciences. He holds a Masters Certificate in Applied Project Management from Villanova University, a Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also completed his Post Graduate Studies and Masters degree at the University of Cambridge.
Brian Holler is a seasoned marketing, sales, and business development leader with over 15 years of experience in tech, startups, professional services, and CPG/retail. He has a proven track record of success in developing and executing strategies that drive growth. In his previous role as COO at Moody’s Medicinals and Greenings, he built the team for and led the development of two businesses – one in hemp, the other in cannabis – from concept to products on shelves. He is also a strong advocate for using data and analytics to inform marketing, sales, and partnership decisions.
At CMS, Brian is responsible for leading the company’s sales, marketing, and business development efforts. He will work closely with the CEO and other senior leaders to develop and execute a strategic plan that will help the company achieve its growth goals. He will also be responsible for building and managing high- performing marketing and sales teams. Brian is a graduate of Boise State University, City University, and Pacific Lutheran University, and holds MA degrees in Communication and Education, and a BA in Media Literacy/Communication.
Dr. Yenugonda is responsible for developing innovative new formulations and improving existing formulations for the company’s core market. He is an accomplished drug discovery and delivery leader with over 20 years of experience in science, technologies, business and management sectors. He has deep expertise in the development of innovative drug delivery technologies for therapeutic modalities expanded beyond small molecules to include nucleic acids, peptides, proteins and antibodies. Dr. Yenugonda’s leadership has led to new initiatives, multi-institutional programs, and multi-investigator grants. He has a proven track record in business development, including academic/pharma/CRO collaborations, evaluation and engaging in licensing and partnership opportunities. Several of his discoveries were licensed to pharma companies for commercial development and helped to initiate spin off start up biopharma companies.
With a master’s in organic chemistry and a Ph.D. in Nanomedicinal Chemistry, he served as a professor and director at Saint John’s Cancer Institute where he established the drug discovery and nanomedicine research program with the aim of developing technologies that improve patient health and enhancing the delivery of therapeutics to its target site, minimizing off-target accumulation and facilitating patient compliance. He has broad scientific knowledge in the drug product development process, including GMP, GLP, CMC, and IND application frameworks. He has contributed and held 3 issued US patents, 2 PCT, and one provisional patent; his scientific contribution is one that stands out by 32 accepted peer-reviewed manuscripts in high-impact journals. He was the recipient of multiple awards for his contribution to chemical research and he is a member of the National Academy of Inventors as well as an adjunct assistant professor at Georgetown University.
Sevan Kesenci joined the CMS team in 2022 providing his experience in e-commerce and logistic planning. Prior to joining CMS, he served as operations manager for United Surplus and Liquidation Inc from 2015-2018.
At CMS, Kesenci has taken on a directive role in all aspects of lab-scale, pilot and large-scale production. He has provided hands-on insight regarding process development, logistics as well as workforce optimization. With his B.A. in Biology from California State University Northridge, he has also taken a lead role in Research & Development relating to formulation science. His background in Biology provides CMS with a wealth of practical knowledge on the human body’s biological pathways as well as the pharmacokinetics of drug delivery.
CMS is looking to partner with biotech, nutraceutical, and wellness companies worldwide and launch innovative products that deliver on the promise of a healthier life.
CMS is looking to partner with biotech, nutraceutical and wellness companies worldwide and launch innovative products that deliver on the promise of a healthier life.